Business Context and Reporting Period
Spyre Therapeutics, Inc. (Nasdaq: SYRE) filed a Form 8-K on June 15, 2026, to disclose positive topline results from Part A of the Phase 2 SKYLINE clinical trial for its investigational drug SPY002. The trial targets the treatment of moderately-to-severely active ulcerative colitis (UC).
Key Financial Metrics
This filing is a current report focused on clinical trial data and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Clinical Results
The filing details significant clinical milestones achieved at Week 12 of the induction period:
- Primary Endpoint: SPY002 met the primary endpoint with a statistically significant 10.7-point reduction in the Robarts Histopathology Index (RHI) score (p<0.0001).
- Clinical Remission: Achieved a 33% clinical remission rate.
- Endoscopic Improvement: Achieved a 42% endoscopic improvement rate.
- Modified Mayo Score: Demonstrated a mean change of -3.7.
- Study Population: Included 48 subjects, 35% of whom were exposed to advanced therapies, with a mean disease duration of 7.0 years.
Outlook, Risks, and Safety Profile
Safety: SPY002 was well-tolerated with a safety profile consistent with the TL1A class.
- Adverse Events: 20 subjects (41.7%) experienced treatment-emergent adverse events (TEAEs).
- Serious Adverse Events (SAEs): Two SAEs were reported (hospitalization for UC exacerbation and worsening heart failure), both deemed not drug-related.
- Discontinuations: Two subjects (4.2%) discontinued due to adverse events.
- Deaths: Zero deaths were reported.
Outlook: Management characterized the results as "among the highest reported in UC," indicating strong potential for the asset. No specific financial guidance or future trial timelines were provided in this filing.
Investor Verification Checklist
- Verify the full statistical analysis plan and detailed data tables in the attached press release (Exhibit 99.1).
- Confirm the timeline for Part B of the SKYLINE trial and subsequent Phase 3 development plans.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Assess the competitive landscape for TL1A inhibitors in ulcerative colitis following these results.